Ottimo Pharma Emerges with David Epstein at Helm, Focusing on Novel PD1/VEGFR2 Bi-Functional Antibody

Leadership:
David Epstein, former CEO of Seagen, has been appointed as Chair & Chief Executive Officer of Ottimo Pharma, a private biotech company.

Company Background:
Ottimo Pharma was co-founded in 2020 by Medicxi and Jonny Finlay, focusing on pioneering cancer therapies for solid tumors.

Product Development:
The company is developing Jankistomig, a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy.

Clinical Plans:
Ottimo Pharma anticipates filing an IND (Investigational New Drug application) in late 2025 for Jankistomig.

Management Team:
The company boasts a world-class leadership team, including Mehdi Shahidi as Head of Development & Chief Medical Officer and James Sabry as Vice-Chair of the Board.

Goal:
Ottimo Pharma aims to improve cancer treatment outcomes and reduce healthcare burden through this novel combination of mechanisms of action.